The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1473
July 20, 2015
View Complete Issue         Table of Contents 2019 
Aptensio XR - Another Long-Acting Methylphenidate for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Aptensio XR - Another Long-Acting Methylphenidate for ADHD
July 20, 2015 (Issue: 1473)
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Aptensio XR - Another Long-Acting Methylphenidate for ADHD
Article code: 1473a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.